Susquehanna International Group
PLX icon

Susquehanna International Group’s Protalix BioTherapeutics PLX Stock Holding History

Susquehanna International Group’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$130K Buy
+59,700
New +$148K ﹤0.01% 12148
2025
Q4 		– Sell
-10,300
Closed -$22.9K – 13308
2025
Q3 		$22.9K Buy
+10,300
New +$16.8K ﹤0.01% 12028
2025
Q2 		– Sell
-10,700
Closed -$27.4K – 13486
2025
Q1 		$27.4K Buy
+10,700
New +$25.6K ﹤0.01% 12037
2024
Q4 		– Sell
-13,000
Closed -$13.3K – 12985
2024
Q3 		$13.3K Buy
+13,000
New +$13.7K ﹤0.01% 11690
2024
Q1 		– Sell
-20,200
Closed -$36K – 13086
2023
Q4 		$36K Sell
20,200
-400
-2% -$622 ﹤0.01% 11832
2023
Q3 		$34.2K Sell
20,600
-23,800
-54% -$42.7K ﹤0.01% 11436
2023
Q2 		$88.8K Sell
44,400
-23,700
-35% -$56.5K ﹤0.01% 11034
2023
Q1 		$143K Buy
68,100
+1,900
+3% +$3.33K ﹤0.01% 10963
2022
Q4 		$90.7K Sell
66,200
-16,700
-20% -$18.3K ﹤0.01% 11042
2022
Q3 		$86K Buy
82,900
+12,000
+17% +$13.3K ﹤0.01% 11817
2022
Q2 		$77K Buy
70,900
+9,200
+15% +$10.8K ﹤0.01% 11699
2022
Q1 		$65K Sell
61,700
-11,400
-16% -$10.4K ﹤0.01% 12172
2021
Q4 		$61K Sell
73,100
-127,700
-64% -$134K ﹤0.01% 12447
2021
Q3 		$267K Sell
200,800
-126,600
-39% -$192K ﹤0.01% 10853
2021
Q2 		$625K Buy
327,400
+156,900
+92% +$540K ﹤0.01% 9026
2021
Q1 		$760K Buy
170,500
+94,000
+123% +$438K ﹤0.01% 8441
2020
Q4 		$278K Buy
76,500
+54,200
+243% +$194K ﹤0.01% 9414
2020
Q3 		$86K Buy
+22,300
New +$80.6K ﹤0.01% 10001
2019
Q4 		– Sell
-1,400
Closed -$3K – 10416
2019
Q3 		$3K Hold
1,400
– – ﹤0.01% 10058
2019
Q2 		$7K Sell
1,400
-9,620
-87% -$40.6K ﹤0.01% 10094
2019
Q1 		$48K Buy
11,020
+20
+0.2% +$90 ﹤0.01% 8470
2018
Q4 		$34K Buy
11,000
+1,000
+10% +$4.75K ﹤0.01% 8585
2018
Q3 		$73K Buy
10,000
+8,200
+456% +$41.2K ﹤0.01% 8721
2018
Q2 		$8K Sell
1,800
-1,810
-50% -$8.04K ﹤0.01% 9472
2018
Q1 		$19K Buy
+3,610
New +$23.8K ﹤0.01% 9126
2016
Q1 		– Sell
-5,060
Closed -$52K – 9504
2015
Q4 		$52K Buy
5,060
+2,890
+133% +$29.4K ﹤0.01% 9095
2015
Q3 		$26K Sell
2,170
-250
-10% -$3.97K ﹤0.01% 9464
2015
Q2 		$47K Buy
2,420
+910
+60% +$18.9K ﹤0.01% 9889
2015
Q1 		$27K Sell
1,510
-4,600
-75% -$90.1K ﹤0.01% 9241
2014
Q4 		$112K Sell
6,110
-7,140
-54% -$153K ﹤0.01% 9151
2014
Q3 		$321K Sell
13,250
-35,570
-73% -$1.02M ﹤0.01% 7925
2014
Q2 		$1.78M Sell
48,820
-16,740
-26% -$675K ﹤0.01% 4877
2014
Q1 		$3M Buy
65,560
+21,340
+48% +$996K ﹤0.01% 3648
2013
Q4 		$1.72M Buy
44,220
+5,610
+15% +$236K ﹤0.01% 4547
2013
Q3 		$1.75M Buy
38,610
+33,180
+611% +$1.7M ﹤0.01% 4327
2013
Q2 		$267K Buy
+5,430
New +$288K ﹤0.01% 7000

Other funds holding PLX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Susquehanna International Group's PLX Position: Q1 2026 in Review

Susquehanna International Group increased its Protalix BioTherapeutics (PLX) stake by 27% in Q1 2026, buying an estimated $26.2K and bringing the position to 49,085 shares worth $107K. The position accounts for ﹤0.01% of the portfolio, ranked #12301.

Susquehanna International Group first reported a position in PLX in Q3 2013 and has held it in 37 quarters since. The position peaked at $2.2M in Q1 2025. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

  • Susquehanna International Group held 49,085 shares of Protalix BioTherapeutics worth $107K as of Q1 2026.
  • Susquehanna International Group bought 10,567 Protalix BioTherapeutics shares in Q1 2026, an estimated $26.2K.
  • Protalix BioTherapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #12301 holding.
  • Susquehanna International Group first reported a position in Protalix BioTherapeutics in Q3 2013 and has held it in 37 quarters since.
  • Susquehanna International Group's Protalix BioTherapeutics position peaked at $2.2M in Q1 2025.
  • 99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.